- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.09. | Kairos Pharma auf der H.C. Wainwright Konferenz: Strategie gegen Medikamentenresistenz im Fokus | 1 | Investing.com Deutsch | ||
| 14.09. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Kairos Pharma to conduct 1-for-7 reverse stock split | 1 | Investing.com | ||
| 21.08. | Kairos Pharma announces 1-for-7 reverse stock split to maintain NYSE compliance | 2 | Seeking Alpha | ||
| 21.08. | Kairos Pharma kündigt Aktienzusammenlegung im Verhältnis 1 zu 7 an | 1 | Investing.com Deutsch | ||
| 21.08. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Kairos Pharma Announces 1-for-7 Reverse Stock Split | 218 | Business Wire | LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct... ► Artikel lesen | |
| 12.08. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.07. | Kairos Pharma Announces Strategic Collaboration With Bayer To Enhance XOFIGO Activity In Metastatic Prostate Cancer | 34 | pulse2.com | ||
| 22.07. | Bayer, Kairos Pharma Collaborate to Boost Xofigo Effectiveness in Metastatic Prostate Cancer | 48 | Contract Pharma | ||
| 22.07. | Kairos Pharma partners with Bayer on prostate cancer study | 53 | Investing.com | ||
| 22.07. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? | 1 | Benzinga.com | ||
| 15.07. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever | 460 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 15.07. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Kairos Pharma signs term sheet to acquire lung cancer asset | 3 | Investing.com | ||
| 04.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 9,090 | +3,41 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| INOVIO PHARMACEUTICALS | 1,058 | -1,76 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,838 | +0,77 % | InflaRx N.V.: InflaRx to Host Virtual Capital Markets Day | ||
| INTELLIA THERAPEUTICS | 10,680 | +0,95 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,420 | +2,98 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,399 | +0,76 % | Breaking News: Weiche zur Nasdaq gestellt | ||
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +2,79 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 7,260 | -1,89 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,515 | +0,27 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,375 | +0,03 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,122 | +1,59 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,042 | +2,56 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| IMMUNIC | 9,574 | +3,26 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 5,685 | -3,64 % | Emergent BioSolutions: Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility |
Das Unternehmen KAIROS PHARMA LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,745 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.